Yarrow Bioscience, Inc. is classed by the SEC under no industry code yet, based in Bridgewater, NJ. Its filings are on EDGAR under CIK 1566044; the figures the desk reads are not on file yet.
Business, industry not on fileBridgewater, NJfilings since 20137 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a business, industry not on file: no industry code on file, so the tenses and readings weigh evenly. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.9 out of ten, 7 of 9 metrics filed and 2 estimated: past 0.7 out of ten, present 4.0 out of ten, future 6.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.4 out of ten. 7 warning events since 2017; the latest 2026-03-11. 4th percentile among 111 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 1.7 out of ten. -23.1% a year over 8 filed years; profitable in 0 of 8. 17th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.1 out of ten. CrossAssetData estimate 0.1/10, confidence 35 of 100 (one part). 1st percentile among 51 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.6 out of ten. ROE -95%: lost 95¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar. 56th percentile among 49 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.5 out of ten. bottom 15% of 12 in its family; net margin -4646.1%. 15th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 35 of 100 (one part). 49th percentile among 61 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 6.4 out of ten. top 36% of 9 in its family for room to expand. 64th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.7 out of ten. top 33% of 8 in its family for growth drivers. 67th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.7 out of ten. top 23% of 7 in its family for expectations against reality. 77th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 for the period ended 2026-07-24 (on EDGAR). Newest filing: Form SCHEDULE 13G, 2026-10-07. Filings on record since 2013. Read from EDGAR 2026-10-12.
Who runs it
Frey, Rebecca (Chief Executive Officer); Domzalski, David (PRESIDENT AND CEO); Basta, Steven L (Chief Executive Officer); Zeronda, Tyler (CHIEF FINANCIAL OFFICER); Alford, Rachael (Chief Operating Officer); Payton, Lori (Chief Development Officer); Ryder, Steven (Chief Medical Officer); Harsch, Mutya (CHIEF LEGAL OFFICER AND GC); Stuart, Iain (CHIEF SCIENTIFIC OFFICER); Ashiya, Mona (director); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.